平衡盐晶体液与生理盐水在危重症成人中的比较
该研究为在学术中心五个重症监护病房进行的实用性、整群随机、多次交叉试验,纳入15,802名成人,根据入住病房的随机化分配接受生理盐水(0.9%氯化钠)或平衡盐晶体液(乳酸林格氏液或Plasma-Lyte A®)。主要结局为30天内主要不良肾脏事件(MAKE30),即死亡、新发肾脏替代治疗或持续性肌酐升高≥基线200%的复合终点,均在出院或30天时截尾。平衡盐晶体液组1,139例(14.3%)发生MAKE30,生理盐水组1,211例(15.4%)(边际比值比0.91;95%置信区间0.84-0.99;条件比值比0.90;95%置信区间0.82-0.99;P=0.04)。30天住院死亡率分别为10.3%和11.1%(P=0.06),新发肾脏替代治疗发生率分别为2.5%和2.9%(P=0.08),持续性肌酐升高发生率分别为6.4%和6.6%(P=0.60)。结论认为,在危重症成人中,使用平衡盐晶体液进行静脉补液相比生理盐水似乎降低了复合结局。
要点
- 在危重症成人中,平衡盐晶体液组MAKE30发生率为14.3%,生理盐水组为15.4%,边际比值比0.91(95%置信区间0.84-0.99),条件比值比0.90(95%置信区间0.82-0.99),P=0.04。
- 30天住院死亡率平衡盐晶体液组10.3% vs 生理盐水组11.1%(P=0.06),新发肾脏替代治疗2.5% vs 2.9%(P=0.08),持续性肌酐升高6.4% vs 6.6%(P=0.60)。
- 研究为在学术中心五个重症监护病房进行的实用性、整群随机、多次交叉试验,纳入15,802名成人。
- 平衡盐晶体液包括乳酸林格氏液或Plasma-Lyte A®,生理盐水为0.9%氯化钠。
适用人群与场景
- 危重症成人,入住学术中心五个重症监护病房,共15,802名。
研究设计与关键结果
- 研究类型:实用性、整群随机、多次交叉试验;样本量15,802名成人;在学术中心五个重症监护病房进行。
- 干预与对照:根据入住病房的随机化分配接受平衡盐晶体液(乳酸林格氏液或Plasma-Lyte A®)或生理盐水(0.9%氯化钠)。
- 主要终点:30天内主要不良肾脏事件(MAKE30),即死亡、新发肾脏替代治疗或持续性肌酐升高≥基线200%的复合终点,均在出院或30天时截尾;平衡盐晶体液组1,139例(14.3%) vs 生理盐水组1,211例(15.4%),边际比值比0.91(95%置信区间0.84-0.99),条件比值比0.90(95%置信区间0.82-0.99),P=0.04。
- 关键次要终点:30天住院死亡率平衡盐晶体液组10.3% vs 生理盐水组11.1%(P=0.06);新发肾脏替代治疗发生率2.5% vs 2.9%(P=0.08);持续性肌酐升高发生率6.4% vs 6.6%(P=0.60)。
证据类型、等级与局限
- 证据类型:实用性、整群随机、多次交叉试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在危重症成人中,使用平衡盐晶体液进行静脉补液相比生理盐水似乎降低了住院死亡率、新发肾脏替代治疗和持续性肾功能不全的复合结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND:: Both balanced crystalloids and saline are used for intravenous fluid administration among critically ill adults. Which results in better clinical outcomes remains unknown.
METHODS:: In a pragmatic, cluster-randomized, multiple-crossover trial in five intensive care units at an academic center, we assigned 15,802 adults to receive saline (0.9% sodium chloride) or balanced crystalloids (lactated Ringer’s solution or Plasma-Lyte A®), according to the randomization of the unit to which they were admitted. The primary outcome was Major Adverse Kidney Events within 30 days (MAKE30), i.e., the composite of death, new renal replacement therapy, or persistent creatinine elevation ≥ 200% of baseline – all censored at the first of hospital discharge or 30 days.
RESULTS:: In the balanced crystalloid group, 1,139 patients (14.3%) experienced MAKE30, compared to 1,211 patients (15.4%) in the saline group (marginal odds ratio, 0.91; 95% confidence interval, 0.84–0.99; conditional odds ratio, 0.90; 95% confidence interval, 0.82–0.99; P=0.04). Thirty-day in-hospital mortality was 10.3% in the balanced crystalloid group and 11.1% in the saline group (P=0.06). The incidence of new renal replacement therapy was 2.5% and 2.9% respectively (P=0.08), and the incidence of persistent creatinine elevation was 6.4% and 6.6% respectively (P=0.60).
CONCLUSIONS:: Among critically ill adults, the use of balanced crystalloids for intravenous fluid administration appeared to reduce the composite outcome of in-hospital mortality, new renal replacement therapy, and persistent renal dysfunction compared with the use of saline. (SMART-MED and SMART-SURG ClinicalTrials.gov numbers, NCT02444988 and NCT02547779.)
参考来源
- Semler MW, Self WH, Rice TW, et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med. 2018. PMID: 29768150. doi:10.1056/NEJMc1804294
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。